I agree with you, I am very disappointed but alas there is still $22M in the bank and years of work on this drug.
There is plenty of scope with TBI and IIH is not going away even with Ozempic.
All is not lost. Hang in there. They've put out the release with the information they had and thank fully have done it now and will pivot from here.
I don't know about directors buying and selling. If i was a biotech exec i wouldn't be throwing in my hard earned given the current macro sentiment around biotech.
Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-108
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
